Treatment of Uterine Sarcoma in NTRK Fusion-Positive Gynecological Sarcoma

NTRK fusion-positive gynecological sarcoma is a molecularly defined, rare subtype of uterine sarcoma. Confirming NTRK fusion status is integral to identifying this patient population and selecting the appropriate treatment strategy, particularly following primary therapy.

Clinical Scenario

NTRK fusion-positive gynecological sarcomas are rare spindle cell tumours resembling fibrosarcomas. This molecularly distinct subgroup requires specific consideration in treatment planning, especially in the recurrent setting.

Treatment Approach (Partial Overview)

For patients with recurrence after primary treatment, a targeted inhibitor approach directed at the NTRK fusion is indicated. The complete evidence-based regimen — including specific agent selection, sequencing, and the supporting evidence base — is detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ijgc-2024-005823

NTRK fusion-positive gynecological sarcomas are rare spindle cell tumors resembling fibrosarcomas.
NTRK inhibitors should be offered to patients with recurrence after primary treatment (III, B).
Most of the data to guide therapy are based on treatment of patients with non-gynecological NTRK fusion sarcomas, where durable response rates of 50–70% with entrectinib and larotrectinib have been reported.

View source ↗